Jeremy Adler, MD, MSc
Manage Your Profile
About
Jeremy Adler, M.D., M.Sc. is a Clinical Professor in the Division of Pediatric Gastroenterology at the University of Michigan and serves as research faculty in the Susan B. Meister Child Health Evaluation and Research (CHEAR) Center. Dr. Adler earned his M.D. degree at the University of South Florida College of Medicine. He completed his residency in pediatrics at Boston City Hospital and Boston Medical Center in 1997. He then practiced academic general pediatrics in New York for several years before moving to Michigan to train in pediatric gastroenterology at the University of Michigan. He then earned a Master of Science in Health and Health Care Research through in the Horace H. Rackham School of Graduate Studies at the University of Michigan, and had further training in the Advanced Improvement Methods program at Cincinnati Children’s Hospital. Dr. Adler joined the pediatric gastroenterology faculty at the University of Michigan in 2008.
Dr. Adler's clinical and research interest is in the care of children and adolescents with Crohn's disease and ulcerative colitis (inflammatory bowel disease or IBD). His research focus is on improving short and long-term outcomes and health related quality of life for children with IBD. He has been working on developing evidence-based strategies for preventing disease related complications such as fistulas and pouchitis, and to mitigate disparities among children with IBD.
Dr. Adler is an NIH-funded researcher whose scientific research has been featured in the American Gastroenterology Association's headline news, on the cover of the journal Inflammatory Bowel Diseases, and in the Innovations in Health Care section of the Wall Street Journal. Dr. Adler is a leader in the field of pediatric IBD, and has served as consultant to the US Food and Drug Administration, and his work on prevention of disease complications and on developing methods for evaluating endoscopic findings has been used in national and international policies and guidelines on treating children and adults with IBD. Dr. Adler also serves as the Director of Research and Quality Improvement in Pediatric Gastroenterology, and as the Director of the Pediatric IBD Program at C.S. Mott Children’s Hospital at Michigan Medicine.
Qualifications
-
Adaptive LeadershipUniversity of Michigan, United states
2024
Other
-
Linkage Leadership AcademyUniversity of Michigan, Ann Arbor, Michigan
2015 - 2015
Other
-
Advanced Improvement Methods (AIM), Center for Health Care QualityCincinnati Children's Hospital Medical Center, Cincinnati, Ohio
2012 - 2013
Other
-
Master of Science in Health and Health Care Research, Robert Wood Johnson Master's ProgramUniversity of Michigan Medical School, Ann Arbor, United States
2008 - 2009
Postdoctoral Research
-
Pediatric gastroenterology FellowshipC. S. Mott Children's Hospital, Ann Arbor, United States
2005 - 2008
Postdoctoral Research
-
Pediatric ResidencyBoston Medical Center, Boston, United States
1994 - 1997
Postdoctoral Research
-
MScHorace H. Rackham School of Graduate Studies, University of Michigan, Ann Arbor, MI, United States
2008 - 2009
-
MDUniversity of South Florida College of Medicine, 4202 E Fowler Ave, Tampa, FL, 33620, United States
1990 - 1994
-
BSUniversity of Florida, Gainesville, FL, United States
1986 - 1990
Center Memberships
-
Center MemberInstitute for Healthcare Policy and Innovation
Research Overview
Dr. Adler focuses on improving care of children and adolescents with Crohn's disease and ulcerative colitis. His research focus is on improving short and long-term outcomes and health related quality of life for children with IBD. He has been working on developing evidence-based strategies for preventing disease related complications such as fistulas and pouchitis, and to mitigate disparities among children with IBD.
Recent Publications
-
Adler J, Galanko JA, Ammoury R, Benkov KJ, Bousvaros A, Boyle B, Cabrera JM, Chun KY, Dorsey J, Ebach DR, Firestine AM, Gulati AS, Herfarth HH, Jester TW, Kaplan JL, Leibowitz I, Linville TM, Margolis PA, Minar P, Molle-Rios Z, Moses J, Olano K, Pashankar DS, Pitch L, Saeed SA, Samson CM, Sandberg K, Steiner SJ, Strople JA, Sullivan JS, Wali PD, Kappelman MD. Am J Gastroenterol, 2025 May 1; 120 (5): 1076 - 1086.Journal ArticleHLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease.
DOI:10.14309/ajg.0000000000003135 PMID: 40315028 -
Adler J, Gadepalli S, Rahman M, Kim S. Gut, 2025 Apr 1; 74 (4): 539 - 546.Journal ArticleEarly tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: Post hoc analysis of the RISK study
DOI:10.1136/gutjnl-2024-333280 PMID: 39667905 -
Adler J, Lin CC, Gadepalli SK, Dombkowski KJ. JAMA Network Open, 2022 Dec 2; 3 (6):Journal ArticleAssociation between Steroid-Sparing Therapy and the Risk of Perianal Fistulizing Complications among Young Patients with Crohn Disease
DOI:10.1001/jamanetworkopen.2020.7378 -
Maltz RM, Adler J. Journal of Pediatric Gastroenterology and Nutrition, 2026 Oct 1; 83 (4): 710 - 716.Journal ArticleInfliximab originator and biosimilars have similar efficacy in children with inflammatory bowel disease
DOI:10.1002/jpn3.70508 PMID: 42535439 -
Van Hecke J, Veereman G, Huysentruyt K, Hauser B, Cools W, Cleymans NF, Adler J, Saeed S, De Greef E. Journal of Pediatric Gastroenterology and Nutrition, 2026 Oct 1; 83 (4): 681 - 691.Journal ArticleThe ImproveCareNow Registry: Prediction of remission rates in paediatric Crohn's disease
DOI:10.1002/jpn3.70519 PMID: 42520290 -
Van Hecke J, Veereman G, Huysentruyt K, Wauters L, Adler J, Saeed S, De Greef E, and the ImproveCareNow Pediatric IBD Learning Health System . JPGN Rep, 2026 Sep 14;Journal ArticleThe ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis.
DOI:10.1002/jpr3.70234 PMID: PMC13574566 -
Saul S, Decaro JJ, Adler J. Gastroenterology and Hepatology, 2026 Sep 1; 22 (9): 461 - 468.Journal ArticleTherapeutic Drug Monitoring in Adolescents and Children With Inflammatory Bowel Disease
-
Patel PV, Moses J, Ali S, Suskind DL, Pasternak B, Kaplan JL, Samson C, Manning L, Adler J, BISCUIT Study Team . Clin Gastroenterol Hepatol, 2026 Aug 22;Journal ArticleAminosalicylate Use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease.
DOI:10.1016/j.cgh.2026.08.008 PMID: 42628666
Featured News & Stories
Family that overcame Crohn’s supports research for future patients
Blake Hardin, MD/MPH student: Merging research and advocacy with medicine
Joanne Constantin, Postdoc: Bridging the fields of public health and medicine
Why anti-TNF drugs don’t work for some kids with Crohn's disease